{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:55:20Z","timestamp":1791366920644,"version":"4.3.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Severe postoperative complications (Clavien-Dindo grade \u22653) occur in 10%\u201330% of patients after curative resection of pancreatic ductal adenocarcinoma (PDAC). Whether adjuvant chemotherapy modifies their impact on long-term survival remains unclear. This study aimed to systematically evaluate the interaction between severe complications and adjuvant chemotherapy after PDAC resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 383 patients with pathologically confirmed PDAC who underwent upfront curative-intent resection at our center between January 2018 and January 2024. Our institutional database initially contained 398 surgical records; 15 records meeting the R2 margin-status or M1-metastasis exclusion criteria were excluded, leaving 383 patients for the primary analysis. Median overall survival (OS) was estimated using the Kaplan\u2013Meier method, and group comparisons were performed with the log-rank test. Covariates adjusted for in the multivariable Cox regression model included age, sex, BMI, tumor differentiation, margin status, vascular invasion, perineural invasion, lymph node ratio, and tumor size. Stratified Cox regression and interaction-effect models were further constructed. Exploratory recurrence-free survival (RFS) analyses defined an event as recurrence or death from any cause. Sensitivity analyses excluded patients with OS &amp;lt;60 days and, additionally, evaluated a 90-day threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Severe complications occurred in 40 of 383 patients (10.4%). Adjuvant chemotherapy was received by 16 of 40 patients (40.0%) in the severe-complication group and 205 of 343 patients (59.8%) in the non-severe-complication group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026). Among patients who did not receive chemotherapy, median OS was significantly shorter in the severe-complication group than in the non-severe-complication group (7.9 vs. 14.6 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001); among those who received chemotherapy, the difference was not statistically significant (18.8 vs. 20.5 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.445). In the interaction model, severe complications were associated with increased mortality in the no-chemotherapy stratum (HR: 4.18, 95% CI: 2.49\u20137.01,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) but not in the chemotherapy stratum (HR: 1.24, 95% CI: 0.66\u20132.34,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.511). In separate stratified Cox models adjusted for the same covariates, adjuvant chemotherapy was associated with lower mortality in the severe-complication group (HR: 0.15, 95% CI: 0.04\u20130.57,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.005), whereas the association was not statistically significant in the non-severe-complication group (HR: 0.76, 95% CI: 0.56\u20131.03,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.075). Exploratory RFS analysis showed shorter RFS among patients with severe complications (median 6.4 vs. 11.1 months; adjusted HR: 1.58, 95% CI: 1.09\u20132.28,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.016).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective cohort, severe complications were associated with worse OS among patients who did not receive adjuvant chemotherapy, whereas the association was not statistically significant among those who received chemotherapy. Because the severe-complication subgroup was small and treatment receipt was subject to postoperative selection, the interaction should be considered hypothesis-generating. These findings do not establish that adjuvant chemotherapy offsets the adverse prognostic association of severe complications and require prospective validation before informing treatment decisions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1968161","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:36:42Z","timestamp":1791365802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interaction between severe postoperative complications and adjuvant chemotherapy on overall survival after upfront resection of pancreatic ductal adenocarcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Shiwei","family":"Wu","sequence":"first","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Wang","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Zou","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"He","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Xue","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Pancreatic Disease Center, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]},{"name":"Department of General Surgery, The First Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101573","DOI":"10.1016\/j.suronc.2021.101573","article-title":"Postoperative morbidity following pancreatic cancer surgery is significantly associated with worse overall patient survival; systematic review and meta-analysis","volume":"38","author":"Mintziras","year":"2021","journal-title":"Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00595-016-1426-1","article-title":"Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review","volume":"47","author":"Watanabe","year":"2017","journal-title":"Surg Today"},{"key":"B12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1245\/s10434-011-2041-4","article-title":"Postoperative complications deteriorate long-term outcome in pancreatic cancer patients","volume":"19","author":"Kamphues","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.ejso.2018.03.024","article-title":"Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy","volume":"44","author":"Lubrano","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.hpb.2021.04.004","article-title":"Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology","volume":"23","author":"Crippa","year":"2021","journal-title":"HPB (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"zrac174","DOI":"10.1093\/bjsopen\/zrac174","article-title":"Impact of complications after resection of pancreatic cancer on disease recurrence and survival, and mediation effect of adjuvant chemotherapy: nationwide, observational cohort study","volume":"7","author":"Henry","year":"2023","journal-title":"BJS Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/gs-2026-1-0008","article-title":"Circulating inflammatory indices refine prognostic stratification and complication risk in pancreatic cancer following radical surgery","volume":"15","author":"Zou","year":"2026","journal-title":"Gland Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/2767-9764.CRC-23-0447","article-title":"Impact of surgery-induced myeloid-derived suppressor cells and the NOX2\/ROS axis on postoperative survival in human pancreatic cancer","volume":"4","author":"Grauers Wiktorin","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1245\/s10434-014-3722-6","article-title":"The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma","volume":"21","author":"Wu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.hpb.2024.11.002","article-title":"Association of chemotherapy completion rates and overall survival with postoperative complications after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma","volume":"27","author":"Kollbeck","year":"2025","journal-title":"HPB (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9335","DOI":"10.1245\/s10434-026-19739-2","article-title":"Do postoperative complications impact adjuvant chemotherapy in patients undergoing left-side pancreatectomy for pancreatic cancer?","volume":"33","author":"Cheung","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00423-025-03933-z","article-title":"Complications following upfront pancreatectomy with venous resection do not compromise adjuvant chemotherapy delivery and survival in pancreatic cancer","volume":"411","author":"Perri","year":"2025","journal-title":"Langenbecks Arch Surg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1002\/cnr2.1390","article-title":"The importance of time-to-adjuvant treatment on survival with pancreatic cancer: a systematic review and meta-analysis","volume":"4","author":"Sugumar","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1245\/s10434-017-5918-z","article-title":"Time to initiation of adjuvant chemotherapy in pancreas cancer: a multi-institutional experience","volume":"24","author":"Xia","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/1120009X.2024.2402175","article-title":"Effect of postsurgical adjuvant chemotherapy timing on outcomes in patients with pancreatic cancer - a systematic review and meta-analysis","volume":"37","author":"Zhou","year":"2025","journal-title":"J Chemother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2468-1253(25)00367-X","article-title":"Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial","volume":"11","author":"Schouten","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1968161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:36:43Z","timestamp":1791365803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1968161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":26,"alternative-id":["10.3389\/fmed.2026.1968161"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1968161","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1968161"}}